CuroNZ is a clinical stage biotechnology company with a drug portfolio covering the peptide family, Neural Regeneration Peptides (NRPs), which were discovered by CuroNZ's founding Director, Dr Frank Sieg and first patented back in 2001.
Our plan for 2017-2018 is to develop the drug candidate NRP2945 to end of IND to make it ready for clinical phase II development with the aim of licensing it or reaching other commercial arrangements to provide a clear pathway forward to bring this promising therapeutic treatment as quickly as possible to patients.
- Drug candidates: Neural Regeneration Peptides (NRPs) of synthetic origin, classified as NCEs
- Internationally granted patent claims for NRP2945 and other NRPs directed to neural regeneration and protection regarding the central nervous system
- In excess of NZ $12 million invested in the development of these class of compounds to date
- Lead compound NRP2945 is in Clinical Phase I study initiated in Melbourne in March 2017 and due to be completed by late 2017
- Unique mechanism of action which produces both regeneration of CNS tissue and anti-inflammatory effects
- Support from the General US-based Fast Forward fund (MS society), from the New Zealand government and private equity investment up to IND
- In 2018, once the IND is approved NRP2945 will be trialled for refractory epilepsy in children diagnosed with Lennox-Gastaut Syndrome (LGS) - Phase II clincial study
- Potential for Orphan drug designation and breakthrough status for NRPs
These exciting peptides have proven efficacy within various neurodegenerative animal disease models indicating significant future therapeutic effects for several human central neural system diseases which currently have few or no treatments and potentially other applications.
Our drug candidate has huge potential, however, we need a pharma partner or clinical phase II investment to enable us to achieve our technical and commercial goals.